QCLS Q/C TECHNOLOGIES, INC.
In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 1321834 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-120.7%
TTM EPS YoY105.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-113.0%
ROA-58.8%
ROIC (approx.)-131.5%
Asset turnover—
Leverage & solvency
Liabilities / assets10.2%
Debt / equity0.00x
Current ratio5.06x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.57x
Accruals ratio-25.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $383,382 | $236,133 | $510,534 | $696,504 | $356,352 | $873,472 | $1.55M | $1.13M |
| SG&A expense | $1.10M | $1.00M | $1.07M | $1.03M | $967,833 | $894,297 | $841,685 | $969,145 |
| Operating income | -$2.57M | -$7.76M | -$3.40M | -$3.71M | -$1.79M | -$1.87M | -$2.47M | -$2.19M |
| Pretax income | -$941,793 | -$6.62M | -$1.24M | -$5.89M | -$2.81M | -$1.80M | -$1.12M | -$2.06M |
| Net income | -$941,793 | -$7.59M | -$2.79M | -$5.89M | -$2.81M | -$1.80M | -$1.12M | -$2.06M |
| EBITDA | -$2.55M | -$7.76M | — | — | -$1.79M | -$1.87M | — | — |
| EPS (basic) | -0.14 | -0.91 | -0.38 | — | -2.50 | -51.10 | -0.36 | — |
| EPS (diluted) | -0.14 | -0.91 | -0.38 | — | -2.50 | -51.10 | -0.36 | — |
| Weighted avg. shares (diluted) | 8.52M | 8.24M | 8.06M | — | 1.48M | 54,261 | 5.35M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $2.59M | $307,612 | $1.13M | $986,996 | $6.90M | $207,553 | $73,244 | $173,154 |
| Short-term investments | $6.81M | $10.68M | $11.85M | $14.80M | $3.09M | $3.61M | $5.81M | $8.35M |
| Current assets | $10.20M | $11.74M | $13.71M | $16.58M | $11.15M | $5.15M | $6.78M | $9.41M |
| PP&E, net | $145,258 | $140,868 | — | — | — | — | — | — |
| Goodwill | $10.50M | $10.50M | $10.50M | $10.50M | $10.50M | $10.50M | $10.50M | $10.50M |
| Intangibles | — | — | $14.09M | $14.09M | — | — | — | — |
| Total assets | $21.28M | $22.87M | $38.29M | $41.17M | $37.23M | $17.15M | $18.78M | $21.42M |
| Current liabilities | $2.02M | $3.57M | $3.69M | $5.53M | $6.53M | $5.55M | $4.94M | $6.70M |
| Total liabilities | $2.18M | $3.79M | $14.60M | $16.44M | $15.91M | $5.55M | $4.94M | $6.70M |
| Shareholders' equity | $16.12M | $16.09M | $20.72M | $21.75M | $14.32M | $5.28M | $8.69M | $9.79M |
| Shares outstanding | 8.50M | 8.19M | 7.85M | 7.69M | 2.98M | 29.38M | 7.39M | 33,636 |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.54M | -$1.82M | -$3.29M | -$3.20M | -$1.16M | -$2.07M | -$2.64M | -$764,115 |
| Capital expenditure | $17,103 | — | — | — | — | — | — | — |
| Free cash flow | -$1.55M | — | — | — | — | — | — | — |
| Investing cash flow | $3.87M | $1.04M | $2.97M | -$11.67M | -$1.49M | $2.20M | $2.54M | $1.10M |
| Financing cash flow | -$55,995 | -$42,896 | $453,930 | $8.95M | — | — | — | -$1.36M |
| Depreciation & amortization | $12,713 | $5,341 | — | — | $0 | $0 | — | — |
| Stock-based compensation | $860,667 | $3.34M | $1.60M | $1.99M | $0 | $104,854 | $84,636 | $83,344 |
Free plan shows the latest 8 periods; Pro shows all 55 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.